Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection

• Andre S. Nell,

  Affiliation PAREXEL Early Phase Clinical Unit, Bloemfontein, South Africa

  ⨯
• Eva D’lom,

  Affiliation PAREXEL International, Madrid, Spain

  ⨯
• Patrick Bouic,

  Affiliation Synexa Life Sciences, Cape Town, South Africa

  ⨯
• Montserrat Sabaté,

  Affiliation TFS Develop, Barcelona, Catalonia, Spain

  ⨯
• Ramon Bosser,

  Affiliation Janus Developments, Barcelona, Catalonia, Spain

  ⨯
• Jordi Picas,

  Affiliation Archivel Farma, Badalona, Catalonia, Spain

  ⨯
• Mercè Amat,

  Affiliation Archivel Farma, Badalona, Catalonia, Spain

  ⨯
• Gavin Churchyard,

  Affiliation The Aurum Institute, Johannesburg, South Africa

  ⨯
• Pere-Joan Cardona

  * E-mail: pj.cardona@gmail.com

  Affiliations Archivel Farma, Badalona, Catalonia, Spain, Unitat de Tuberculosi Experimental (UTE), Institut per a la Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain

  ⨯